In Compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, Glaxosmithkline Pharmaceuticals has informed that it enclosed a copy of the Certificate received from Kfin Technologies, the Registrar and share Transfer Agent of the Company, for the quarter ended 30th June 2024.
The above information is a part of company’s filings submitted to BSE.